High-dose Daunorubicin Therapy for Acute Nonlymphocytic Leukemia: Correlation of Response and Toxicity with Pharmacokinetics and Intracellular Daunorubicin Reductase Activity
Overview
Affiliations
Effective combination of cold physical plasma and chemotherapy against Ewing sarcoma cells in vitro.
Nitsch A, Qarqash S, Romer S, Schoon J, Singer D, Bekeschus S Sci Rep. 2024; 14(1):6505.
PMID: 38499701 PMC: 10948386. DOI: 10.1038/s41598-024-56985-4.
Nitsch A, Qarqash S, Romer S, Schoon J, Ekkernkamp A, Niethard M Int J Mol Sci. 2023; 24(10).
PMID: 37240019 PMC: 10218459. DOI: 10.3390/ijms24108669.
Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.
Varatharajan S, Panetta J, Abraham A, Karathedath S, Mohanan E, Lakshmi K Cancer Chemother Pharmacol. 2016; 78(5):1051-1058.
PMID: 27738808 PMC: 7115946. DOI: 10.1007/s00280-016-3166-8.
Phase I study of liposomal daunorubicin in patients with acute leukemia.
Cortes J, OBrien S, Estey E, Giles F, Keating M, Kantarjian H Invest New Drugs. 1999; 17(1):81-7.
PMID: 10555126 DOI: 10.1023/a:1006216001681.
Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines.
Robert J Cancer Chemother Pharmacol. 1993; 32(2):99-102.
PMID: 8485814 DOI: 10.1007/BF00685610.